Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder

October 2009

Reps will promote Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder.

They will point out that Saphris (asenapine) seems well tolerated.

Saphris does seem to cause less weight gain and other metabolic problems than risperidone or Zyprexa (olanzapine).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza using antivirals and vaccines for the current flu season
computer alert about possible serotonin syndrome when patients get more than one serotonergic drug
Respiratory & Allergy new OTC cough and cold syrup called Clofera (chlophedianol/pseudoephedrine)
Cardiology whether a DOUBLE dose of clopidogrel (Plavix) improves outcomes in cardiac patients
Diabetes questions about how to switch between insulins
Women's Health You'll hear more about limiting antidepressants during pregnancy
Women's Health whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives
Statins questions about resolving statin myopathy
Neurology & Pain Embeda (im-BED-a) is a new oral opioid designed to limit abuse
Psychiatry Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder
Ophthalmology Claritin Eye and Zyrtec Itchy Eye Drops don't contain the active ingredient that you'd expect